Vaxess Technologies announced they raised $12 million in funding. The Cambridge based company is developing a shelf-stable MIMIX skin patch for vaccines and therapeutics. The new funding will continue to advance their work on GLP-1, in vivo work with mRNA, and grow their manufacturing capabilities. Vaxess Technologies was awarded a $1 million Accelerator Loan from the MLSC, a funding program intended for early-stage life sciences companies in Massachusetts.
